^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

EGFR R776C

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
Associations
11ms
Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M
|
Ivesa (firmonertinib)
12ms
Phase classification • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 exon 20 insertion • EGFR G719X • EGFR S768I • EGFR G724S • HER-2 exon 23 mutation • EGFR R776C • EGFR V774M
|
Ivesa (firmonertinib)
over2years
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
P2, N=30, Recruiting, Shanghai Chest Hospital | Trial primary completion date: Mar 2022 --> Oct 2022
Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
|
Vizimpro (dacomitinib)
over2years
Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations. (PubMed, J Cancer Res Clin Oncol)
This case first identified a patient with lung squamous cell carcinoma harboring uncommon compound EGFR mutation (G719A and R776C) benefited from afatinib and achieved 11 months of progression-free survival (PFS). Then, new MYC amplification was detected after disease progression, indicating that MYC amplification may be one of the reasons for afatinib resistance.
Journal
|
EGFR (Epidermal growth factor receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
EGFR mutation • MYC amplification • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR G719A + EGFR R776C • EGFR R776C
|
Gilotrif (afatinib)
almost4years
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
P2, N=30, Recruiting, Shanghai Chest Hospital | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
|
Vizimpro (dacomitinib)
over4years
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (clinicaltrials.gov)
P2, N=30, Not yet recruiting, Shanghai Chest Hospital
Clinical • New P2 trial
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR G719A • EGFR L747P • EGFR exon 18 mutation • EGFR T854A • EGFR D761Y • EGFR L861R • EGFR E709Q • EGFR E746 • EGFR I744_K745insKIPVAI • EGFR L747S • EGFR R776H • EGFR G779C • EGFR R776C
|
Vizimpro (dacomitinib)